Anaemia management during the study
| Patients not on dialysis (n=524) | Kidney transplant patients (n=92) | |||||
|---|---|---|---|---|---|---|
| Initial ESA treatment | Initial ESA treatment | |||||
| Naïve (n=253) | ESA-treated (n=271) | Total (n=524) | Naïve (n=22) | ESA-treated (n=70) | Total (n=92) | |
| At baseline | ||||||
| C.E.R.A. | ||||||
| Dose schedule (n (%)) | ||||||
| Once a month | 123 (48.6) | 230 (84.9) | 353 (67.4) | 12 (54.5) | 44 (62.9) | 56 (60.9) |
| Once every 2 weeks | 130 (51.4) | 41 (15.1) | 171 (32.6) | 10 (45.5) | 26 (37.1) | 36 (39.1) |
| Initial monthly dose* (µg) | 86.8±32.9 | 108.9±67.0 | 98.2±54.4 | 108.0±45.2 | 133.9±75.5 | 127.7±70.1 |
| First injection given by†(n (%)) | ||||||
| Home nurse | 217 (87.5) | 209 (78.3) | 426 (82.7) | 10 (45.5) | 15 (21.7) | 25 (27.5) |
| Patient | 23 (9.3) | 46 (17.2) | 69 (13.4) | 11 (50.0) | 48 (69.6) | 59 (64.8) |
| Family member | 8 (3.2) | 12 (4.5) | 20 (3.9) | 1 (4.5) | 6 (8.7) | 7 (7.7) |
| Other treatments | ||||||
| Iron (n (%)) | 114 (45.1) | 90 (33.2) | 204 (38.9) | 11 (50.0) | 31 (44.3) | 42 (45.7) |
| Folic acid‡(n (%)) | 43 (17.1) | 38 (14.0) | 81 (15.5) | 8 (36.4) | 24 (34.3) | 32 (34.8) |
| Vitamin B12‡(n (%)) | 10 (4.0) | 4 (1.5) | 14 (2.7) | 0 | 0 | 0 |
| Around 6 months | ||||||
| Number | 175 | 208 | 383 | 18 | 50 | 68 |
| C.E.R.A. | ||||||
| Dose schedule (n (%)) | ||||||
| Once a month | 143 (81.7) | 188 (90.4) | 331 (86.4) | 14 (77.8) | 41 (82.0) | 55 (80.9) |
| Once every 2 weeks | 29 (16.6) | 19 (9.1) | 48 (12.5) | 4 (22.2) | 9 (18.0) | 13 (19.1) |
| Monthly dose*(µg) | 87.5±50.9 | 113.4±77.7 | 101.5±68.0 | 94.7±47.8 | 135.4±81.0 | 124.6±75.5 |
| During first 6 months | ||||||
| Number | 249 | 270 | 519 | 21 | 68 | 89 |
| At least one dose adjustment (n (%)) | 143 (57.4) | 132 (48.9) | 275 (53.0) | 8 (38.1) | 39 (57.4) | 47 (52.8) |
| Type of dose adjustment (n (%)) | ||||||
| Dose increase | 55 (22.1) | 57 (21.1) | 112 (21.6) | 4 (19.0) | 15 (22.1) | 19 (21.3) |
| Increase and decrease | 19 (7.6) | 17 (6.3) | 36 (6.9) | 0 | 8 (11.8) | 8 (9.0) |
| Dose decrease | 69 (27.7) | 58 (21.5) | 127 (24.5) | 4 (19.0) | 16 (23.5) | 20 (22.5) |
*Mean±SD.
†Two missing data in non-dialysis patients.
‡One missing data in non-dialysis patients.
C.E.R.A., continuous erythropoietin receptor activator; ESA, erythropoiesis-stimulating agent.